S&P 500 Healthcare Sector SEC Filings — July 31, 2026

Net earnings surged 44.3% YoY to $1,276M, driven by a 49.1% jump in operating income, reflecting strong operational leverage and lower impairments. This outperformance vs. the broader med-tech peer group is a clear positive signal.

Total revenues grew 10.5% YoY to $11,994M, a strong acceleration that signals robust demand across its life sciences tools and services portfolio, outpacing many large-cap healthcare peers.

Adjusted diluted EPS grew 22.9% YoY to $3.65, significantly outpacing revenue growth of 10.2%, demonstrating excellent margin expansion and operational efficiency.

Immunology portfolio grew 15.1% and neuroscience grew 20.3%, showing strong momentum in key growth drivers that are successfully offsetting the -35.9% decline in Humira.

An EVP sold a small number of shares ($9.83K) under a 10b5-1 plan. While the trade is pre-planned and low materiality, it is the only insider sale in the cohort and warrants monitoring for any acceleration.

Net product sales declined 17.5% YoY to $94M, highlighting the company's struggle to replace COVID-19 vaccine revenue with its pipeline. The failed norovirus vaccine (mRNA-1403) Phase 3 trial is a major pipeline setback.

Cash and investments fell by $0.6B in a single quarter to $6.9B, with a further $950M paid for litigation in July 2026. The cash burn rate is accelerating and is unsustainable without new revenue streams.

The disclosure of a material cybersecurity incident involving exfiltration of proprietary data and patient PHI is a significant operational and reputational risk, creating near-term uncertainty for the stock.

Despite strong revenue growth, cash and cash equivalents plummeted from $9,852M to $4,064M, driven by $8,872M in acquisitions and $4,000M in share buybacks, signaling aggressive capital allocation that is levering up the balance sheet.

Cash and cash equivalents declined 15.5% to $3,391M, and net cash used in financing activities swung to a $1,605M outflow from a $1,545M inflow a year ago, reflecting significant debt repayments and dividend payments that are consuming cash.

The failure of norovirus candidate mRNA-1403 at Phase 3 is a high-impact risk, removing a key pipeline catalyst. Combined with a $0.6B quarterly cash burn and a further $950M litigation payout, the company faces a severe liquidity crunch.

The confirmed exfiltration of proprietary data and patient PHI from third-party cloud environments is a material event. The ongoing investigation could reveal further liabilities, regulatory fines, and litigation, creating a prolonged overhang.

Long-term debt surged to $39,181M from $35,852M, while cash collapsed. The $8.9B in acquisitions and $4B in buybacks have significantly increased financial risk, making the company more vulnerable to rising interest rates or an economic downturn.

Net product sales fell 17.5% YoY, and total revenue growth of only 2.1% YoY was entirely dependent on a surge in 'other revenue'. The core business is shrinking, and the pipeline is failing to fill the gap.

Humira continued its steep decline (-35.9% reported), and while being offset now, the absolute dollar loss is substantial. Any slowdown in the growth of Skyrizi or Rinvoq would expose AbbVie to significant revenue headwinds.

The Vascular segment was flat YoY ($496M vs $498M), and Spinal Implants sales collapsed to $3M from $5M (and $5M YTD from $171M) post-divestiture. These areas show no organic growth and are a drag on the overall portfolio.

While small, the sale by an EVP is the only insider transaction in the entire cohort. In a sector with strong earnings, a lack of insider buying and any selling can be a subtle negative signal about management's view of the stock's valuation.

Total assets fell to $10.961B from $12.338B, while liabilities increased to $4.200B. Retained earnings dropped to $5.098B from $7.223B, reflecting cumulative losses that are eroding the company's equity base.

Restructuring and other costs rose to $98M in Q2 2026 from $82M in Q2 2025, suggesting ongoing operational challenges or integration costs from the large M&A program.

With immunology (+15.1%) and neuroscience (+20.3%) driving strong growth, and adjusted EPS up 22.9%, AbbVie is successfully transitioning. The narrowed guidance ($13.87-$14.07) provides clarity, and the Apogee acquisition ($10.9B) adds a potential new pipeline catalyst.

Operating income surged 49.1% on 9.4% revenue growth, demonstrating massive operating leverage. As the company integrates acquisitions and optimizes its cost structure, further margin expansion is a key catalyst for earnings upgrades.

The 10.5% YoY revenue growth is a significant acceleration and signals strong end-market demand. If the company can successfully integrate its large acquisitions and begin to de-lever, the stock could re-rate higher.

The net loss narrowed 5% YoY to $(0.8)B, and the company improved its GAAP operating expense outlook by ~$0.2B. If management can execute on cost-cutting and stabilize the cash burn, the current pessimism could create a buying opportunity.

With adjusted EPS growing 22.9% and a strong pipeline, AbbVie may be undervalued relative to its growth rate, especially if the Apogee deal delivers on its promise. The high adjusted operating margin (48.3%) is a key competitive advantage.

As a dominant player in orthopedics and medical devices, Stryker's 9.4% revenue growth outpaces many peers. Its strong pricing power and innovative product cycle provide a durable competitive moat.

The $8.9B in acquisitions signals a bold strategy to consolidate the life sciences tools space. If these deals are accretive and drive cross-selling, Thermo Fisher could emerge as an even more dominant player with enhanced pricing power.

Despite the norovirus failure, Moderna's platform technology still holds promise. The company's reiterated plan for up to 10% revenue growth in 2026 suggests management sees a path forward, potentially through new vaccine approvals or partnerships.

Stryker (+9.4% rev) and Thermo Fisher (+10.5% rev) delivered strong, broad-based growth, while AbbVie's core pharma business (ex-Humira) is accelerating. In contrast, Moderna's product sales are declining (-17.5%), highlighting the high-risk/high-reward nature of pure-play biotech. The market is rewarding established, diversified business models.

Across the cohort, companies are aggressively using cash for M&A and buybacks. Thermo Fisher spent $12.9B on acquisitions and buybacks, Stryker is consuming cash for debt repayment, and Moderna is burning cash on operations. This trend increases financial leverage and reduces financial flexibility, a key risk if the economy slows.

Amgen's disclosure of a material breach involving proprietary data and patient PHI is a stark reminder of the sector's vulnerability. This event will likely increase scrutiny on all healthcare companies' cybersecurity protocols and could lead to higher compliance costs and insurance premiums across the sector.

AbbVie's success in replacing Humira with Skyrizi and Rinvoq is driving its outperformance. Conversely, Moderna's failed norovirus trial underscores the binary risk of biotech pipelines. The market is placing a premium on companies with proven, late-stage pipeline assets and diversified revenue streams.

Stryker's 49.1% operating income surge and AbbVie's 22.9% adjusted EPS growth show that margin expansion is a powerful lever for earnings, even when revenue growth is in the single digits. Companies with pricing power and operational efficiency are being rewarded.

Monitor for further disclosures on the scope of the data breach, potential regulatory fines (e.g., HIPAA), and any litigation. The next earnings call will be critical for management to address the financial and operational impact. [Ongoing]

Watch for any updates on the norovirus program's next steps and the company's plan to stem cash burn. The Q3 2026 results will be crucial to see if the cash position stabilizes or continues to deteriorate. [Next Earnings: Q3 2026]

Monitor for regulatory approval and the closing of the ~$10.9B deal. The integration and pipeline progress of Apogee's assets will be a key catalyst for AbbVie's long-term growth story. [Expected Close: H2 2026]

Watch for updates on the integration of its large acquisitions and any plans to de-lever the balance sheet. The company's ability to generate free cash flow to pay down debt will be a key metric for investors. [Next Earnings: Q3 2026]

Monitor the flat Vascular segment for any signs of a turnaround or further deterioration. Any new product launches or M&A in this area could be a catalyst. [Next Earnings: Q3 2026]

While the recent sale was small, watch for any acceleration of insider selling or the emergence of insider buying, which would provide a clearer signal on management's view of the stock. [Ongoing]

Accounts receivable dropped sharply to $17M from $184M, a massive 90.8% decline. This could indicate a severe drop in sales or a change in payment terms. This metric needs close monitoring in the next quarter. [Next Filing: 10-Q Q3 2026]